AU Patent

AU2013255752B2 — Glucagon-like-peptide-2 (GLP-2) analogues

Assigned to Zealand Pharma AS · Expires 2017-11-09 · 9y expired

What this patent protects

GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis, treatment or ameliorating of the gast…

USPTO Abstract

GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013255752B2
Jurisdiction
AU
Classification
Expires
2017-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Zealand Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.